(Q37641368)

21 August 2017

1 reference

title

Receptor-mediated tumor targeting based on peptide hormones (English)

1 reference

21 August 2017

2

Marilena Manea

1 reference

21 August 2017

1

Gábor Mezo

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Drug Delivery

21 August 2017

published in

1 reference

21 August 2017

volume

7

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

79-96

1 reference

Chemotherapy targeted to cancers through tumoral hormone receptors

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Peptide receptors as molecular targets for cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Newly recognized GnRH receptors: function and relative role

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Intracellular gonadotropin-releasing hormone receptors in breast cancer and gonadotrope lineage cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

A novel mammalian receptor for the evolutionarily conserved type II GnRH

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Arrestin-mediated ERK activation by gonadotropin-releasing hormone receptors: receptor-specific activation mechanisms and compartmentalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

New derivatives of GnRH as potential anticancer therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

New approaches to the therapy of various tumors based on peptide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Synthesis, characterization, and metabolic stability of porphyrin-peptide conjugates bearing bifunctional signaling sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Design, synthesis, and in vitro activity of novel drug delivery systems containing tuftsin derivatives and methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Novel polymeric prodrug with multivalent components for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Targeted proapoptotic anticancer drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Mammalian type I gonadotropin-releasing hormone receptors undergo slow, constitutive, agonist-independent internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Hypothalamic hormones and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

An adjustable release rate linking strategy for cytotoxin-peptide conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Immunotoxicity of ethyl carbamate in female BALB/c mice: role of esterase and cytochrome P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Study of inhibitory effects of an antiangiogenic somatostatin-camptothecin conjugate on laser-induced choroidal neovascularization in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Imaging of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

99mTc-HYNIC octreotide in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

Somatostatin, its receptors and analogs, in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903418410

10.1517/17425240903418410

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference